In the assessment of 12-month price targets, analysts unveil insights for Alnylam Pharmaceuticals, presenting an average target of $420.41, a high estimate of $570.00, and a low estimate of $333.00.

Garlic tastes divine, but something that packs so much punch is bound to have plenty of myths surrounding it. We're here to ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $406.0, a high ...

Disc Medicine has charted a route to market for its bitopertin drug for rare disease erythropoietic protoporphyria.

Congenital erythropoietic porphyria (CEP) is a rare autosomal recessive disorder characterised by a deficiency of uroporphyrinogen III synthase (UROS), a pivotal enzyme in the haem biosynthetic ...

A 19-year-old woman with a history of depression and anxiety symptoms was admitted to the hospital because of seizure, ...

Hospitalists working in behavioral health centers face unique challenges, including limited resources and complex patient ...

Alnylam is to file its givosiran with regulators to treat a form of the blood disease porphyria, applying its gene silencing technology to the condition for the first time, following supportive ...

The title of physician conferred a certain cachet when Dr. Jack Sternberg, a retired medical oncologist, entered medicine.

Nucleic acid therapies offer targeted treatment for genetic diseases, but delivery remains a key hurdle. Explore how advances ...

The Windsors have always exuded an air of mystique, so it's not surprising there are so many wild royal family conspiracy ...

Market Wrap Clinuvel (CUV) Shares in biopharmaceutical company Clinuvel have recently benefited from positive preliminary results in its phase three porphyria trial. Updated Dec 22, 2009 Joyce ...